Trump admits reimbursing lawyer Michael Cohen $130,000 for hush-money payment to Stormy Daniels

Jun 4: A malaria drug President Donald Trump took to try to prevent COVID-19 proved ineffective for that in the first large, high-quality study to test it in people in close contact with someone with the disease.

Results published Wednesday by the New England Journal of Medicine show that hydroxychloroquine was no better than placebo pills at preventing illness from the coronavirus.

The drug did not seem to cause serious harm, though -- about 40% on it had side effects, mostly mild stomach problems.

 “We were disappointed. We would have liked for this to work,” said the study leader, Dr. David Boulware, an infectious disease specialist at the University of Minnesota.

“But our objective was to answer the question and to conduct a high-quality study,” because the evidence on the drug so far has been inconclusive, he said.

Hydroxychloroquine and a similar drug, chloroquine, have been the subject of much debate since Trump started promoting them in March.

Hydroxychloroquine has long been used for malaria, lupus, and rheumatoid arthritis, but no large studies have shown it or chloroquine to be safe or effective for much sicker patients with coronavirus, and some studies have suggested the drugs may do harm.

Trump took a two-week course of hydroxychloroquine, along with zinc and Vitamin D, after two staffers tested positive for COVID-19, and had no ill effects, according to results of his latest physical released by his doctor Wednesday.

Federal regulators have warned against hydroxychloroquine's use except in hospitals and formal studies because of the risk of side effects, especially heart rhythm problems.

Boulware's study involved 821 people in the United States and Canada living with someone diagnosed with COVID-19 or at high risk of getting it because of their job -- doctors, nurses, ambulance workers who had significant exposure to a sick patient while not wearing full protective gear.

They were randomly assigned to get either the nutrient folate as a placebo or hydroxychloroquine for five days, starting within four days of their exposure. Neither they nor others involved in the research knew who was getting which pills.

After 14 days in the study, 12 per cent on the drug developed COVID-19 symptoms versus 14 per cent in the placebo group, but the difference is so small it could have occurred by chance, Boulware said.

“There's basically no effect. It does not prevent infection,” he said of the drug. Even if it were to give some slim advantage, “we'd want a much larger effect” to justify its use and risk of side effects for preventing illness, he said.

Results were no different among a subgroup of participants who were taking zinc or vitamin C, which some people believe might help make hydroxychloroquine more effective or fight the coronavirus.

There are some big caveats: The study enrolled people through the Internet and social media, relying on them to report their own symptoms rather than having them tracked in a formal way by doctors.

Participants were not all tested for the coronavirus but were diagnosed as COVID-19 cases based on symptoms in many cases. And not all took their medicines as directed.

The results “are more provocative than definitive,” and the drug may yet have prevention benefits if tried sooner or in a different way, Dr. Myron Cohen of the University of North Carolina at Chapel Hill wrote in a commentary in the journal.

Others were glad to see a study that had a comparison group and good scientific methods after so many weaker reports on hydroxychloroquine.

“This fits with everything else we've seen so far which suggests that it's not beneficial," said Dr. Peter Bach, director of a health policy center at Memorial Sloan Kettering Cancer Center in New York.

This study was in younger relatively healthy people, but the results “would make me very discouraged about trying to use this in older people” who are most vulnerable to serious illness from the coronavirus, Bach said.

“If it does work, it doesn't work very well.” Dr. Dan Culver, a lung specialist at the Cleveland Clinic, said there's still a chance that giving the drug sooner than four days after someone's exposure to the virus may help prevent illness.

But the study “takes 'home run' off the table” as far as hopes for the drug, he said.

The study was mostly funded by David Baszucki, founder of Roblox, a California-based game software company, and other private donors and the Minnesota university.

Boulware also is leading a study testing hydroxychloroquine for treating COVID-19. The study is finished and results are being analyzed now.

On Tuesday, the journal Lancet posted an “expression of concern” about a study it published earlier this month of nearly 15,000 COVID-19 patients on the malaria drugs that tied their use to a higher risk of dying in the hospital or developing a heartbeat problem.

Scientists have raised serious questions about the database used for that study, and its authors have launched an independent audit.

That work had a big impact: the World Health Organization suspended use of hydroxychloroquine in a study it is leading, and French officials stopped the drug's use in hospitals. On Wednesday, the WHO said experts who reviewed safety information decided that its study could resume.

Jun 10: Indian-origin California Senator Kamala Harris has joined former vice president and 2020 Democratic presidential nominee Joe Biden to raise USD 3.5 million for the upcoming November elections.

Tuesday's fundraiser is the second-largest single event haul so far for the Biden campaign, which raised USD 4 million at one event earlier this month.

Harris' presence during the virtual mega fund raiser assumes significance as the Democratic Party leaders consider her to be one of the front-runners to be the nominee for vice president. The 55-year-old lawyer-politician was once considered to be a strong opponent of Biden in the 2020 Democratic primaries.

Introducing Harris to the 1,400 supporters present at the event, Biden underlined the history-breaking nature of her past electoral wins.

"For much of her career, she was the only person in the room who looked like she did," he said.

At the start of the campaign last year, Harris was very critical of Biden. She later endorsed him, months after she decided to withdraw herself from the race to the White House.

During the fundraiser, Harris was effusive in her praise for Biden.

Referring to Biden's meeting with George Floyd's family, she said, "He (Biden)is someone who whether one on one or speaking to the nation always has a sense of how people are experiencing this world, and what their needs are...This moment in the history of our country really represents an extraordinary exercise in contrast."

"On the other hand, we have a Donald Trump who had the gall to dispatch the US military to clear the streets so that he could prance down and then, like a prop, hold up the bible for a photo op," Harris said.

The death of African-American Floyd during police confinement in Minneapolis on May 25 has resulted in widespread protests not only in the US but across the world.

"There are so many contrasts between Joe Biden and Donald Trump that really point to the choice that we as Americans have today," Harris said.

California Lt Governor Eleni Kounalakis also joined the fund raiser.

In his remarks, Biden, 77, said the US is reeling in anguish and anger over the brutal killing of Floyd or the systemic racism that still infects every part of the society. "Harris knows better than anybody," he said.

"At the same time, we're facing the worst economic disaster since the Great Depression. American history is not a fairy tale with a guaranteed ending, a happy ending. This is a battle for the soul of the country.

"It's been a constant tug of war between the American ideal that we all are created equal -- and the harsh reality that racism has long torn us apart...I'm going to ask every American to look where we are now and to think, is this who we are? Is this who we want to be?" Biden asked.

Participating in the questions and answers session, Harris said America has still not fully embraced, acknowledged or addressed its history of racism and its current history of racism.

"One can think of this moment as an inflection moment, and it will require bold action and it will require immediate action...This stresses the importance and the immediacy and the urgency of electing Joe Biden," she said.

Replying to a question, Biden said, "Did you see today where the President of the United States while George Floyd was being buried, was condemning the older man who was knocked down with his head bleeding and everyone walking by. Did you see that? I mean, my lord. What have we become if we abide by this? So much we can do and must do."

Harris said the election is going to be rough and tumble.

"There are very powerful forces that thrive off of the hate and division that Donald Trump has been sowing. This is not going to be easy. And we have about just a few months to get this thing done," she said.

Feb 14: R K Pachauri, a former chief of The Energy and Resources Institute, passed away on Thursday after a prolonged cardiac ailment, TERI Director General Ajay Mathur said.

He was 79.

"It is with immense sadness that we announce the passing away of R K Pachauri, the founder Director of TERI. The entire TERI family stands with the family of Dr Pachauri in this hour of grief," Mathur said in a statement issued by the TERI.

"TERI is what it is because of Dr Pachauri's untiring perseverance. He played a pivotal role in growing this institution, and making it a premier global organisation in the sustainability space," said Mathur, who succeeded Pachauri at TERI in 2015. Pachauri was admitted to Escorts Heart Institute in the national capital where he underwent open heart surgery and was put on life support on Tuesday, sources said.

In the statement issued by TERI, its Chairman Nitin Desai hailed Pachauri's contribution to global sustainable development as "unparalleled".